Fosun Pharma to cancel 897,140 restricted A-shares

Shanghai Fosun Pharmaceutical Group (SSE: 600196) announced it will proceed with the repurchase and cancellation of 897,140 restricted A-shares on May 30, 2025. The decision follows approval at board and supervisory meetings on April 11, 2025. The cancellation is attributed to two main factors: departures of some initial and reserved grant incentive recipients and failure to meet 2024 performance targets outlined in the company's A-share incentive plan. The total repurchase price for the shares amounted to CNY 19,100,110.60. The cancellation will reduce the company's total share capital from 2,671,326,465 shares to 2,670,429,325 shares; however, the holdings of the controlling shareholder, Shanghai Fosun High Technology (Group), and its concerted parties will remain unchanged, but their proportional ownership will slightly increase. The company has fulfilled creditor notification procedures, and legal counsel has provided opinions confirming compliance with relevant regulations.